Trial · NCT01266070

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

NCT01266070, Phase 2, Terminated, M.D. Anderson Cancer Center; results first posted 2017-02-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. TKI 258 in Von Hippel-Lindau Syndrome (VHL). Trials, record NCT01266070. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01266070

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: TKI 258 in Von Hippel-Lindau Syndrome (VHL)
NCT number: NCT01266070
Status: Terminated
Phases: Phase 2
Enrollment: 6 participants, actual
Lead sponsor: M.D. Anderson Cancer Center
Conditions: Von Hippel-Lindau Syndrome
Interventions: Dovitinib
First posted: 2010-12-24
Last updated: 2017-02-13
Results first posted: 2017-02-13

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Most Frequent & Most Serious Adverse Events: Safety of Dovitinib for 6 Months	Every 2 cycles (approximately 8 weeks) for 6 months	Most frequent \& Most Serious Adverse Events: Safety of treatment with Dovitinib for 6 months in participants with VHL who have a measurable hemangioblastoma undergoing surveillance evaluated by toxicity scored using Common Toxicity Criteria (CTC) Version 4.0.
Secondary	Number of VHL Participants With Response at 6 Months	Every 2 cycles (approximately 8 weeks) for 6 months	Efficacy of treatment with dovitinib for 6 months in patients with VHL who have a measurable lesion evaluated by response using RECIST (Response Evaluation Criteria in Solid Tumors): Complete Response, Partial Response, Progressive Disease or Stable Disease.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Most Frequent & Most Serious Adverse Events: Safety of Dovitinib for 6 Months	Every 2 cycles (approximately 8 weeks) for 6 months		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of VHL Participants With Response at 6 Months	Every 2 cycles (approximately 8 weeks) for 6 months		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group13

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Most Frequent & Most Serious Adverse Events: Safety of Dovitinib for 6 Months	Dovitinib	Alanine aminotransferase increased	6	Participants
Most Frequent & Most Serious Adverse Events: Safety of Dovitinib for 6 Months	Dovitinib	Alkaline phosphatase increased	6	Participants
Most Frequent & Most Serious Adverse Events: Safety of Dovitinib for 6 Months	Dovitinib	Aspartate aminotransferase increased	6	Participants
Most Frequent & Most Serious Adverse Events: Safety of Dovitinib for 6 Months	Dovitinib	Diarrhea	5	Participants
Most Frequent & Most Serious Adverse Events: Safety of Dovitinib for 6 Months	Dovitinib	Dyspepsia	3	Participants
Most Frequent & Most Serious Adverse Events: Safety of Dovitinib for 6 Months	Dovitinib	GGT Increased	5	Participants
Most Frequent & Most Serious Adverse Events: Safety of Dovitinib for 6 Months	Dovitinib	Hyperglycemia	4	Participants
Most Frequent & Most Serious Adverse Events: Safety of Dovitinib for 6 Months	Dovitinib	Hyperkalemia	4	Participants
Most Frequent & Most Serious Adverse Events: Safety of Dovitinib for 6 Months	Dovitinib	Mucositis oral	4	Participants
Most Frequent & Most Serious Adverse Events: Safety of Dovitinib for 6 Months	Dovitinib	Nausea	6	Participants

1 to 10 of 13Source ClinicalTrials.gov

See all 13 results by group

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Dovitinib	6
Overall Study	COMPLETED	Dovitinib	2
Overall Study	NOT COMPLETED	Dovitinib	4

Source ClinicalTrials.gov

Adverse events43

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal pain	General disorders	Dovitinib	1	6	1
other	Agitation	Psychiatric disorders	Dovitinib	1	6	1
other	Alanine aminotransferase increased	Investigations	Dovitinib	6	6	12
other	Alkaline phosphatase increased	Investigations	Dovitinib	6	6	7
other	Anxiety	Psychiatric disorders	Dovitinib	1	6	1
other	Aspartate aminotransferase increased	Investigations	Dovitinib	5	6	5
other	Blurred vision	Eye disorders	Dovitinib	1	6	1
other	Cholesterol high	Investigations	Dovitinib	1	6	1
other	Creatinine increased	Investigations	Dovitinib	1	6	1
other	Depression	Psychiatric disorders	Dovitinib	1	6	1

1 to 10 of 43Source ClinicalTrials.gov

See all 43 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Dovitinib
Total, other adverse events	Dovitinib	6	6
Total, serious adverse events	Dovitinib	0	6

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
34783716	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01266070

GET https://conductscience.org/api/trials/v1/NCT01266070/events?page=2

API reference For AI assistants